drulletje drie schreef op 11 mei 2016 15:38:
Galapagos earns $10M milestone from AbbVie from start of early-stage CF study
The start of a Phase 1 clinical trial assessing potentiator GLPG2451 in cystic fibrosis (CF) triggers a $10M milestone payment to Galapagos NV (NASDAQ:GLPG) from collaboration partner AbbVie (NYSE:ABBV). The randomized, double-blind, placebo-controlled, dose-ranging study in healthy volunteers is being conducted in the Netherlands and Belgium. Top-line results should be available in Q4.
GLPG2451 is the second potentiator to enter clinical trials. The first, GLPG1837, is currently being evaluated in a Phase 2 trial, SAPHIRA 1, in CF patients with G551D and S1251N mutations. Top-line results are expected in H2.
Previously: AbbVie and Galapagos expand CF partnership; potential milestones increased to $600M (April 29)
Previously: Second mid-stage study underway for Galapagos's CF candidate GLPG1837 (March 22)
seekingalpha.com/news/3182300-galapag...